New hope for eradication of HIV from the body: The role of polymeric nanomedicines in HIV/AIDS pharmacotherapy

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Lenjisa, Jimma L ^a   Woldu, Minyahil A ^a   Satessa, Gizaw D ^a  

^a AMBO UNIVERSITY   (Ethiopia)

Author keywords

Antiretrovirals; HIV AIDS; Nano polymers; Nanomedicines

Indexed keywords

BIOCHEMISTRY; DISEASE CONTROL; DRUG INTERACTIONS; POLYMERS; VIRUSES;

ANTIRETROVIRALS; APPLICATION OF POLYMERS; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HIV/AIDS; HUMAN IMMUNODEFICIENCY VIRUS; INTRACELLULAR CONCENTRATION; NANO-POLYMERS; NANOMEDICINES;

DISEASES;

CARBOXYMETHYLCELLULOSE; DENDRIMER; EFAVIRENZ; ETHYL CELLULOSE; LAMIVUDINE PLUS ZIDOVUDINE; NANOCARRIER; PENTASACCHARIDE; POLYMER; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BIOAVAILABILITY; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; DISEASE ERADICATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MONOTHERAPY; NANOMEDICINE; NANOTECHNOLOGY; REVIEW; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; HIV; HIV INFECTIONS; HUMANS; NANOMEDICINE; POLYMERS;

EID: 84899136983     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-12-9     Document Type: Review

References (36)

1. Esmaeil AP. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomed J 2013, 1(1):1-12.
2. De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008, 3(2):133-149.
3. Cutlers Gardens The Nanotech Revolution in Drug Delivery. 2007, 1-11. http://www.Cientifica.Com, accessed on 30/10/2013, Cutlers Gardens.
4. Volker W, Barbel H, Sibylle G, Anne-Katrin B. European Commission Joint Research Centre. Institute for Prospective Technological Studies. 2008, Luxembourg: Nanomedicine: Drivers for development and possible impacts, http://www.jrc.ec.europa.eu or http://ipts.jrc.ec.europa.eu. Accessed on 30/10/2013.
5. Nilesh J, Ruchi J, Navneet T. Nanotechnology: a safe and effective drug delivery system. Asia Pac J Clin Res 2010, 3(3):1-7.
6. Nelson AO, Patrick OO, Ndidi CN. Nanostructures for drug delivery. Trop J Pharm Res 2009, 8(3):275-287.
7. Jones M-C, Leroux J-C. Polymeric micelles-a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999, 48(2):101-111. 10.1016/S0939-6411(99)00039-9, 10469928.
8. Yamamoto T, Yokoyam M, Opanasopit P. What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J Controlled Release 2007, 123:11-18.
9. Armstead AL, Bingyun L. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomed 2011, 6:3281-3293.
10. Stevenson M. HIV-1 pathogenesis. Nat Med 2003, 9:853-860. 10.1038/nm0703-853, 12835705.
11. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998, 280(1):67-71. 10.1001/jama.280.1.67, 9660366.
12. Sonza S, Crowe SM. Reservoirs for HIV infection and their persistence in the face of undetectable viral load. AIDS Patient Care STDS 2001, 15:511-518. 10.1089/108729101753205676, 11689138.
13. Crowe SM. Macrophages and residual HIV infection. Curr Opin HIV AIDS 2006, 1:129.
14. Kay MS. Silent, but deadly - eliminating reservoirs of latent HIV. Trends Biotechnol 2003, 2:420-423.
15. UNAIDS Global Report: UNAIDS Report on global AIDS epidemic. 2013, Access on 09/10/2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdfLi, UNAIDS.
16. Amiji MM, Vyas TK, Shah LK. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov Med 2006, 6(34):157-162.
17. Research Spotlight Nanomedicines for HIV therapy20th Conference on Retroviruses and Opportunistic Infections Atlanta. 2013, Accessed on 10/11/2013. http://www.natap.org/2013/CROI/CROI.htm, Research Spotlight.
18. Woodrow KA, Cu Y, Booth CJ. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009, 8:526-533. 10.1038/nmat2444, 2693358, 19404239.
19. Raveen P, Glenn EMM, Patrick G, Hendrik GK. Nanotechnology and the Treatment of HIV Infection. Viruses 2012, 4:488-520. 10.3390/v4040488, 3347320, 22590683.
20. Shahriar P, Peidi H. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage targeted PEG-fMLF (N-Formyl- Methionyl-Leucyl-Phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res 2007, 24(11):2110-2119. 10.1007/s11095-007-9402-5, 2682207, 17701325.
21. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)- protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-1277. 10.1016/S0169-409X(03)00108-X, 14499706.
22. Vinogradov SV, Larisa Y. Nano-NRTIs: efficient Inhibitors of HIV Type-1 in macrophages with a reduced mitochondrial toxicity. Antivir Chem Chemother 2011, 21(1):1-14.
23. Thierry H, Olivier K, Dominique S. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
24. Sumit B, Biswajit M, Samrat Roy C. Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study. Int J Nanomed 2012, 7:6049-6061.
25. Jianqing P, Zhenghong W, Xiaole Q, Yi C, Xiangbo L. Dendrimers as potential therapeutic tools in HIV inhibition. Molecules 2013, 18:7912-7929. 10.3390/molecules18077912, 23884127.
26. Isabella B, David L, Marco R. Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One 2013, 8(10):e76482. 10.1371/journal.pone.0076482, 3792046, 24116111.
27. Jiehua Z, Preston Neff C, Xiaoxuan L. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 2011, 19(12):2228-2238. 10.1038/mt.2011.207, 3242666, 21952167.
28. Sushama T, Katie M, Adam J. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res 2011, 90(3):195-199. 10.1016/j.antiviral.2011.03.186, 3115201, 21459115.
29. Evrim AT, Ozge I, Tamer B. Studies on transdermal delivery enhancement of zidovudine. AAPS Pharm Sci Tech 2009, 10(1):88-97.
30. Chiappetta DA, Hocht C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanomedicine 2010, 5(1):11-23. 10.2217/nnm.09.90, 20025460.
31. Chiappetta DA, Hocht C, Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Current HIV Research 2009, 8(3):223-31.
32. Simon C. First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27--31 March 2011. Magaliesberg, South Africa, Available at: http://i-base.info/htb/14934. Accessed on 11/12/2013.
33. Christopher JD, Todd B, Michael G, Annemarie SH, Michael AB. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother 2010, 65:2183-2187. 10.1093/jac/dkq318, 2941676, 20729545.
34. Sankara V, Madhura KL, Nilaykumar P. Formulation and in-vitro evaluation of zidovudine-lamivudine nanoparticles. Ind J Pharm Edu Res. 2012, 46(2):192-196.
35. Annemarie S, Emily M, Alex P. Polymeric nanoparticles containing combination antiretroviral drugs for HIV Type 1 treatment. AIDS Res Hum Retroviruses 2013, 29(5):746-755. 10.1089/aid.2012.0301, 23289671.
36. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010, 62:491-502. 10.1016/j.addr.2009.11.019, 19931328.